Mark A. Lemmon, Ph.D., F.R.S.
Yale University
H-index: 93
North America-United States
Top articles of Mark A. Lemmon, Ph.D., F.R.S.
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Glycoproteomic landscape and structural dynamics of TIM family immune checkpoints enabled by mucinase SME and molecular dynamics simulations | Biophysical Journal | Mia A Rosenfeld Fiona L Kearns Joann Chongsaritsinsuk Alexandra Steigmeyer Keira E Mahoney | 2024/2/8 |
Distinct interactions stabilize EGFR dimers and higher-order oligomers in cell membranes | Cell reports | Krishna C Mudumbi Eric A Burns David J Schodt Zaritza O Petrova Anatoly Kiyatkin | 2024/1/23 |
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma | Nature Communications | Esther R Berko Gabriela M Witek Smita Matkar Zaritza O Petrova Megan A Wu | 2023/5/5 |
Allosteric activation of the co-receptor BAK1 by the EFR receptor kinase initiates immune signaling | bioRxiv | Henning Mühlenbeck Yuko Tsutsui Mark A Lemmon Kyle W Bender Cyril Zipfel | 2023/8/24 |
Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations | Clinical Cancer Research | Michael J Grant Jacqueline V Aredo Jacqueline H Starrett Paul Stockhammer Iris K van Alderwerelt van Rosenburgh | 2023/6/1 |
Dynamics of protein kinases and pseudokinases by HDX-MS | Joshua B Sheetz Mark A Lemmon Yuko Tsutsui | 2022/1/1 | |
Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations | Nature communications | Iris K van Alderwerelt van Rosenburgh David M Lu Michael J Grant Steven E Stayrook Manali Phadke | 2022/11/10 |
Looking lively: emerging principles of pseudokinase signaling | Joshua B Sheetz Mark A Lemmon | 2022/10/1 | |
A Prosperous Future | J. Biochem. | Mark A Lemmon | 2022/9 |
Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias | Nature | Chun Hu Carlos A Leche Anatoly Kiyatkin Zhaolong Yu Steven E Stayrook | 2022/2/17 |
Glioblastoma mutations impair ligand discrimination by EGFR | bioRxiv | Chun Hu Carlos A Leche Anatoly Kiyatkin Steven E Stayrook Kathryn M Ferguson | 2021/5/4 |
Structural basis for ligand reception by anaplastic lymphoma kinase | Nature | Tongqing Li Steven E Stayrook Yuko Tsutsui Jianan Zhang Yueyue Wang | 2021/12/2 |
Drugging the “undruggable” MYCN oncogenic transcription factor: overcoming previous obstacles to impact childhood cancers | Adam J Wolpaw Richard Bayliss Gabriele Büchel Chi V Dang Martin Eilers | 2021/4/1 | |
ROR and RYK extracellular region structures suggest that receptor tyrosine kinases have distinct WNT-recognition modes | Cell reports | Fumin Shi Jeannine M Mendrola Joshua B Sheetz Neo Wu Anselm Sommer | 2021/10/19 |
Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation | Proceedings of the National Academy of Sciences | Keshav Patil Earl Joseph Jordan Jin H Park Krishna Suresh Courtney M Smith | 2021/3/9 |
Phosphatidylserine binding directly regulates TIM-3 function | Biochemical Journal | Courtney M Smith Alice Li Nithya Krishnamurthy Mark A Lemmon | 2021/9/17 |
Abstract PO032: TIM3 regulation by phosphatidylserine | Cancer Immunology Research | Courtney M Smith Alice Li Nithya Krishnamurthy Mark A Lemmon | 2021/2/1 |
Phosphatidylserine binding regulates TIM-3 effects on T cell receptor signaling | bioRxiv | Courtney M Smith Alice Li Nithya Krishnamurthy Mark A Lemmon | 2021/5/8 |
Regulation of TIM-3 by Phosphatidylserine | Courtney McCaul Smith | 2021 | |
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations | Cancer research | Jacqueline H Starrett Alexis A Guernet Maria Emanuela Cuomo Kamrine E Poels Iris K van Alderwerelt van Rosenburgh | 2020/5/15 |
Co-Authors
